Abstract
Twenty-two consecutive carbapenem-resistant enterobacterial isolates were recovered from patients hospitalized between January and April 2013 in different units at a university hospital in Istanbul, Turkey. These were Klebsiella pneumoniae isolates producing the carbapenemases OXA-48, NDM-1, and KPC-2, Enterobacter cloacae isolates producing NDM-1, and Escherichia coli isolates producing OXA-48. Most of the OXA-48-producing K. pneumoniae and all the NDM-1-producing E. cloacae were clonally related. The NDM-1-producing E. cloacae isolates recovered from a single neonatal intensive care unit corresponded to a single cluster, highlighting the spread of that clone in that setting.
TEXT
Carbapenem-hydrolyzing β-lactamases belonging to Ambler classes A, B, and D have been reported worldwide among Enterobacteriaceae (1, 2). In Turkey, the wide dissemination of OXA-48-producing isolates (from Klebsiella pneumoniae, Escherichia coli, Citrobacter freundii, and Enterobacter cloacae) has been demonstrated, defining this country as being endemic for OXA-48 (3–5). Apart from OXA-48 producers, isolates producing other types of carbapenemases (NDM-1, IMP-1, and KPC-2) were recently identified in Turkey as well. The non-OXA-48-producing carbapenemase producers reported from Turkey are the following: six NDM-1-producing K. pneumoniae isolates (6, 7), four IMP-1-producing K. pneumoniae isolates (7, 8), and a single KPC-2-producing K. pneumoniae isolate (9).
The spread of NDM-1-producing Enterobacteriaceae is now considered to be almost global (10). However, only a few outbreaks of NDM-1 producers have been reported. So far, most of the reports from many countries have been scattered and corresponded mainly to importation cases (1).
Our study was designed to evaluate retrospectively the occurrence of carbapenemase-producing Enterobacteriaceae in a university hospital in Istanbul, Turkey. An increased number of carbapenem-resistant isolates recovered from patients hospitalized in the neonatal intensive care unit (NICU) during a short period prompted us to perform such a study.
All enterobacterial isolates presenting with reduced susceptibility to imipenem (MIC ≥ 0.5 μg/ml) were collected between 1 January and 1 May 2013 (a 4-month period), consisting of a total of 22 isolates. The MICs of the carbapenems were determined by the Etest (AB bioMérieux, La Balme-les-Grottes, France) on Mueller-Hinton agar plates at 37°C, and the results of susceptibility testing were interpreted according to CLSI guidelines (11). Those isolates were recovered mostly from urine samples, and also from rectal swabs (Table). All isolates were considered to be colonizers. These were K. pneumoniae (n = 12), E. cloacae (n = 8), and E. coli (n = 2) (Table 1). The isolates were resistant to all β-lactams, including carbapenems for most isolates (Table 2). However, some isolates were still categorized in the susceptible range for carbapenems (Table 2). In addition, they were mostly resistant to aminoglycosides, fluoroquinolones, chloramphenicol, sulfonamides, fosfomycin, and nitrofurantoin. All except two of them had low MIC values (<0.5 μg/ml) for colistin, as measured by the Etest.
TABLE 1.
Features of the carbapenem-resistant isolates and patient characteristics
Patient/strain no. | Date of isolation (mo/day/yr) | Isolate | Site of isolationa | Carbapenemase produced | Associated β-lactamase(s) | 16S rRNA methylase | Sequence type | Hospitalization unitb | Patient age |
---|---|---|---|---|---|---|---|---|---|
1 | 01/25/2013 | K. pneumoniae | Urine | NDM-1 | CTX-M-15 + CMY-6 + SHV-1 | RmtC | ST15 | Internal medicine | 60 yr |
2 | 02/13/2013 | K. pneumoniae | ETA | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | ICU | 31 yr |
3 | 02/25/2013 | K. pneumoniae | ETA | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | ICU | 56 yr |
4 | 03/09/2013 | K. pneumoniae | Body fluid | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | Orthopedics | 73 yr |
5 | 03/13/2013 | E. coli | Body fluid | OXA-48 | CTX-M-3 + OXA-1 + TEM-1 | None | NDc | Gynecology | 65 yr |
6 | 03/30/2013 | E. cloacae | ETA | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | Newborn |
7 | 04/02/2013 | E. cloacae | Urine | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | 3 mo |
8 | 04/03/2013 | E. cloacae | Urine | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | 4 mo |
9 | 04/03/2013 | E. cloacae | Rectal swab | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | Newborn |
10 | 04/06/2013 | E. cloacae | Urine | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | Newborn |
11 | 04/09/2013 | E. cloacae | Nasal swab | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | 3 mo |
12 | 04/10/2013 | E. coli | Urine | OXA-48 | CTX-M-15 | None | ND | Pediatrics | 7 yr |
13 | 04/16/2013 | E. cloacae | Rectal swab | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | 1 mo |
14 | 04/21/2013 | E. cloacae | Rectal swab | NDM-1 | CTX-M-15 + OXA-1 | RmtC | ND | NICU | 4 mo |
15 | 04/24/2013 | K. pneumoniae | Urine | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | ICU | 12 yr |
16 | 04/04/2013 | K. pneumoniae | Rectal swab | NDM-1 | CTX-M-3 + SHV-27 | RmtC | ST1059 | NICU | Newborn |
17 | 04/04/2013 | K. pneumoniae | Rectal swab | NDM-1 | OXA-1 + SHV-1 | RmtC | ST45 | NICU | Newborn |
18 | 04/04/2013 | K. pneumoniae | Rectal swab | NDM-1 | OXA-1 + SHV-27 | RmtC | ST278 | NICU | Newborn |
19 | 04/29/2013 | K. pneumoniae | Urine | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | Neurosurgery | 12 yr |
20 | 04/30/2013 | K. pneumoniae | BAL fluid | OXA-48 | CTX-M-15 + OXA-1 + TEM-1 + SHV-1 | None | ST101 | Pneumology | 60 yr |
21 | 04/30/2013 | K. pneumoniae | Skin tissue | KPC-2 | OXA-9 + SHV-1 + TEM-1 | None | ST307 | Plastic surgery | 64 yr |
22 | 04/30/2013 | K. pneumoniae | Urine | KPC-2 | OXA-9 + SHV-1 + TEM-1 | None | ST307 | Plastic surgery | 12 yr |
ETA, endotracheal aspirate; BAL, bronchoalveolar lavage.
ICU, intensive care unit; NICU, neonatal intensive care unit.
ND, not determined.
TABLE 2.
MICs of carbapenems and coresistance to non-β-lactam antibiotics
Patient/strain no. | Isolate | Carbapenemase produced | MIC (μg/ml) of carbapenemsa |
Coresistancesb | ||
---|---|---|---|---|---|---|
IMP | MER | ERT | ||||
1 | K. pneumoniae | NDM-1 | 2 | 4 | 16 | TET SUL RIF AMK GEN TOB |
2 | K. pneumoniae | OXA-48 | 1 | 1 | 4 | SUL AMK GEN TOB FQ FOS |
3 | K. pneumoniae | OXA-48 | 0.5 | 2 | 8 | TET GEN TOB FQ CHL |
4 | K. pneumoniae | OXA-48 | 0.5 | 2 | 8 | TET GEN TOB FQ CHL |
5 | E. coli | OXA-48 | 0.5 | 0.25 | 0.5 | SUL RIF FOS |
6 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
7 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
8 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
9 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
10 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
11 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
12 | E. coli | OXA-48 | 0.5 | 0.25 | 0.5 | SUL RIF FOS |
13 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
14 | E. cloacae | NDM-1 | 8 | 4 | 8 | TET SUL RIF AMK GEN TOB |
15 | K. pneumoniae | OXA-48 | 1 | 4 | 8 | TET SUL RIF GEN TOB FQ |
16 | K. pneumoniae | NDM-1 | 4 | 4 | 8 | TET SUL RIF AMK GEN TOB COL |
17 | K. pneumoniae | NDM-1 | 4 | 4 | 4 | TET SUL RIF AMK GEN TOB |
18 | K. pneumoniae | NDM-1 | 4 | 2 | 8 | TET SUL RIF AMK GEN TOB |
19 | K. pneumoniae | OXA-48 | 1 | 4 | 16 | TET RIF GEN TOB FOS COL |
20 | K. pneumoniae | OXA-48 | 8 | 8 | 16 | TET SUL GEN TOB FQ CHL FOS |
21 | K. pneumoniae | KPC-2 | 2 | 4 | 8 | RIF FQ FOS |
22 | K. pneumoniae | KPC-2 | 2 | 4 | 8 | RIF FQ FOS |
IMP, imipenem; MER, meropenem; ERT, ertapenem.
TET, tetracycline; SUL, sulfonamides; RIF, rifampin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; FQ, fluoroquinolones (ciprofloxacin and ofloxacin); COL, colistin (indicated when the MIC was not <0.5 μg/ml); CHL, chloramphenicol; FOS, fosfomycin.
Carbapenemase detection was performed using the Carba NP test (12), and positive results were obtained for the 22 isolates. Thus, PCR assays were carried out with a series of primers designed to detect Ambler class A, B, and D carbapenemase genes, i.e., blaKPC, blaIMP, blaVIM, blaNDM, and blaOXA-48 (13), followed by sequencing of the PCR amplicons. Two isolates were positive for blaKPC-2, 12 for blaNDM-1 gene, and eight for blaOXA-48 (Table 1). None of the isolates coharbored two carbapenemase genes. Note that the two KPC-2-producing isolates were K. pneumoniae, the 12 NDM-1-producing isolates were K. pneumoniae (n = 4) and E. cloacae (n = 8), and the eight OXA-48-producing isolates were K. pneumoniae (n = 6) and E. coli (n = 2) (Table 1).
Genotyping was performed to evaluate the clonal relationship of the K. pneumoniae and E. cloacae isolates by pulsed-field gel electrophoresis (PFGE) (14), and K. pneumoniae isolates were additionally genotyped by multilocus sequence typing (MLST), as described previously (15). The two KPC-2-producing K. pneumoniae isolates were clonally related and belonged to the sequence type 307 (ST307). The four NDM-1-producing K. pneumoniae isolates were clonally unrelated, belonging to ST15, ST45, ST278, and ST1059. The eight NDM-1-producing E. cloacae isolates were clonally undistinguishable by PFGE, thus corresponding to a single clone. Finally, the six OXA-48-positive K. pneumoniae isolates were all clonally related and belonged to ST101 (Table 1).
Interestingly, looking at the hospitalization wards from which the patients originated, it appeared that a cluster of colonizing NDM-1-producing E. cloacae isolates occurred in the NICU, with a total of eight neonates harboring this same resistant strain. Similarly, the two patients colonized with the KPC-2-producing K. pneumoniae isolates had been hospitalized in the same ward (plastic surgery). Regarding the dissemination of the ST101 and OXA-48-producing K. pneumoniae isolates (five patients colonized in four distinct wards), a nosocomial route of dissemination might be also suspected. However, this hypothesis is not obvious considering that OXA-48-producing K. pneumoniae are very widespread in Turkey, and taking into account the heterogeneity observed in terms of antibiotic resistance for those isolates, the MICs of carbapenems, and coresistance markers (Table 2). Interestingly, ST101 and OXA-48-producing K. pneumoniae isolates have been reported in Libya (16) and were at the origin of an outbreak in Spain (17). In contrast, and even if OXA-48-producing K. pneumoniae isolates of many different STs have been identified in Turkey (18), that specific clone was never identified in that country. Considering the recent and frequent transfers of Libyan patients to Turkey, and in particular in the hospital where those samples have been recovered, this might explain the emergence of that specific clone.
Note that the majority of the NDM-1-positive isolates, regardless of their clonal lineage and of the species to which they belonged, were multidrug resistant. In particular, most of them coexpressed the extended-spectrum β-lactamase CTX-M-15 and the narrow-spectrum β-lactamase OXA-1, as identified by PCR and sequencing (19) (Table 1). In addition, since all NDM-1-positive isolates were resistant at a high level to all aminoglycosides, a search of 16S rRNA methylase-encoding genes was performed as described previously (20). The results showed that all those isolates (eight E. cloacae and the four K. pneumoniae isolates) were positive for the rmtC gene (21).
In order to evaluate whether the cooccurrence of the blaNDM-1 and the rmtC genes might be related to the spread of a specific plasmid, mating-out assays were performed using all those isolates as donors and with E. coli J53 as the recipient, as described previously (22). Interestingly, E. coli transconjugants coproducing NDM-1 and RmtC were obtained for all the isolates, and a single plasmid of ca. 150 kb was identified in all transconjugants. That plasmid additionally conferred resistance to rifampin to all transconjugants. However, it did not harbor the blaCTX-M-15 gene, in accordance with the susceptibility to aztreonam (a substrate spared by NDM-1) (23) observed for all E. coli transconjugants. Attempts to type this plasmid using the PCR-based replicon typing (24) remained unsuccessful. PCR mapping was performed to identify the genetic sequences surrounding the blaNDM-1 gene in all positive isolates. The same structure was found, with the blaNDM-1 gene preceded by a truncated version of ISAba125, followed by the bleMBL gene encoding resistance to bleomycin (25). Similar structures were identified previously in different species from different countries (19).
Our study reports an outbreak of NDM-1-producing E. cloacae in a NICU setting and describes the emergence of plasmid-mediated 16S rRNA methylases in Turkey. Here, the RmtC enzyme was involved and was encoded by a gene located on the same plasmid carrying the blaNDM-1 gene. Such an association between those two genes was previously reported in a single K. pneumoniae isolate from India (19) and in a series of K. pneumoniae isolates from Kenya (26). A 150-kb and untypeable plasmid coharboring the two genes was similarly identified here and in the Indian isolate. The wide spread of multidrug-resistant NDM-1 producers in a NICU setting is extremely worrisome, since infections developed by those immunocompromised patients are very difficult to treat. While this work was in progress, an outbreak of NDM-1-producing K. pneumoniae was also reported in a neonatal unit located in Bogotá, Colombia (27). In that study, two out of the six infected newborns died. The strain involved corresponded to ST1043, which is unrelated to the STs identified in our study.
In many countries, the occurrence of NDM-1 producers in hospitalized patients is mostly related to previous patient hospitalization on the Indian subcontinent. Nevertheless, the first case of NDM-1-producing K. pneumoniae in Turkey was related to a transfer from Iraq (8). While this work was in progress, another study showed the emergence of NDM-1-producing K. pneumoniae isolates in a Turkish hospital located in Kayseri, the center of Turkey, which is 800 km from Istanbul (7), further emphasizing the actual NDM-1 producer problem in Turkey and therefore identifying a possible hidden reservoir for those multidrug-resistant isolates. In that study, as in ours, the origin of the NDM-1-producing isolates is unknown. Altogether, those studies indicate that the spread of NDM-1 producers in the Middle East may be more important than was suspected and is now likely out of control.
This clinical experience was interesting since an outbreak was suspected as soon as two similar carbapenem-resistant E. cloacae isolates were recovered from two different patients in the NICU, which is a 30-bed unit. Nasal and rectal swabs were obtained from all 30 patients, and 10 more swabs were obtained from the incubators and environment (a total of 70 surveillance cultures). None of the swabs from the incubators and environment grew carbapenem-resistant Enterobacteriaceae (CRE). In order to detect the flaws in work practices causing this colonization, a hospital video surveillance system was used, and significant compromises in the infection control procedures were identified, especially during night shifts. A detailed and rigorous infection control training program was therefore performed, in which all staff participated. Contact isolation precautions were strictly implemented with all the patients who were positive for CRE, and after 30 to 45 days, there were no patients in the NICU who were infected or colonized with any CRE organism, and there has not been a single case since then (8 months). This further shows that complementary works between the clinical and microbiological units may contribute significantly to preventing the spread of CRE.
ACKNOWLEDGMENTS
This work was mostly funded by the INSERM (France) and the University of Fribourg (Switzerland) and by grants from the European Community (R-GNOSIS, FP7/HEALTH-F3-2011-282512, and MAGIC-BULLET, FP7/HEALTH-F3-2001-278232).
Footnotes
Published ahead of print 18 February 2014
REFERENCES
- 1.Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol. Med. 18:263–272. 10.1016/j.molmed.2012.03.003 [DOI] [PubMed] [Google Scholar]
- 2.Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791–1798. 10.3201/eid1710.110655 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67:1597–1606. 10.1093/jac/dks121 [DOI] [PubMed] [Google Scholar]
- 4.Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P. 2010. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54:1369–1373. 10.1128/AAC.01312-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Glasner C, Albiger B, Buist G, Tambić Andrasević A, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Donker T, Monnet DL, Grundmann H, European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group 2013. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 18:20525 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20525 [DOI] [PubMed] [Google Scholar]
- 6.Poirel L, Ozdamar M, Ocampo-Sosa AA, Türkoglu S, Ozer UG, Nordmann P. 2012. NDM-1-producing Klebsiella pneumoniae now in Turkey. Antimicrob. Agents Chemother. 56:2784–2785. 10.1128/AAC.00150-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Alp E, Perçin D, Colakoğlu S, Durmaz S, Kürkcü CA, Ekincioğlu P, Güneş T. 2013. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey. J. Hosp. Infect. 84:178–180. 10.1016/j.jhin.2013.03.002 [DOI] [PubMed] [Google Scholar]
- 8.Aktas Z, Bal C, Midilli K, Poirel L, Nordmann P. 2006. First IMP-1-producing Klebsiella pneumoniae isolate in Turkey. Clin. Microbiol. Infect. 12:695–696. 10.1111/j.1469-0691.2006.01480.x [DOI] [PubMed] [Google Scholar]
- 9.Poirel L, Labarca J, Bello H, Rioseco ML, Bernabeu S, Nordmann P. 2013. Emergence of the 16 rRNA methylase RmtG in an extended-spectrum β-lactamase producing and colistin-resistant Klebsiella pneumoniae, Chile. Antimicrob. Agents Chemother. 58:618–619. 10.1128/AAC.02059-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol. 19:588–595. 10.1016/j.tim.2011.09.005 [DOI] [PubMed] [Google Scholar]
- 11.Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23 Clinical and Laboratory Standards Institute, Wayne, PA [Google Scholar]
- 12.Nordmann P, Poirel L, Dortet L. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 18:1503–1507. 10.3201/eid1809.120355 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70:119–123. 10.1016/j.diagmicrobio.2010.12.002 [DOI] [PubMed] [Google Scholar]
- 14.Haertl R, Bandlow G. 1993. Epidemiological fingerprinting of Enterobacter cloacae by small-fragment restriction endonuclease analysis and pulsed-field gel electrophoresis of genomic restriction fragments. J. Clin. Microbiol. 31:128–133 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J. Clin. Microbiol. 43:4178–4182. 10.1128/JCM.43.8.4178-4182.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lafeuille E, Decré D, Mahjoub-Messai F, Bidet P, Arlet G, Bingen E. 2013. OXA-48 carbapenemase-producing Klebsiella pneumoniae isolated from Libyan patients. Microb. Drug Resist. 19:491–497. 10.1089/mdr.2012.0219 [DOI] [PubMed] [Google Scholar]
- 17.Pitart C, Solé M, Roca I, Fàbrega A, Vila J, Marco F. 2011. First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob. Agents Chemother. 55:4398–4401. 10.1128/AAC.00329-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Potron A, Poirel L, Rondinaud E, Nordmann P. 2013. Intercontinental spread of OXA-48 ß-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill. 18:20549 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20549 [DOI] [PubMed] [Google Scholar]
- 19.Poirel L, Dortet L, Bernabeu S, Nordmann P. 2011. Genetic features of blaNDM-1-positive Enterobacteriaceae. Antimicrob. Agents Chemother. 55:5403–5407. 10.1128/AAC.00585-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Berçot B, Poirel L, Nordmann P. 2008. Plasmid-mediated 16S rRNA methylases among extended-spectrum β-lactamase-producing Enterobacteriaceae isolates. Antimicrob. Agents Chemother. 52:4526–4527. 10.1128/AAC.00882-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Wachino J, Yamane K, Shibayama K, Kurokawa H, Shibata N, Suzuki S, Doi Y, Kimura K, Ike Y, Arakawa Y. 2006. Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a Proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob. Agents Chemother. 50:178-184. 10.1128/AAC.50.1.178-184.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. 2010. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54:4914–4916. 10.1128/AAC.00878-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046–5054. 10.1128/AAC.00774-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63:219–228. 10.1016/j.mimet.2005.03.018 [DOI] [PubMed] [Google Scholar]
- 25.Dortet L, Nordmann P, Poirel L. 2012. Association of the emerging carbapenemase NDM-1 with a bleomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother. 56:1693–1697. 10.1128/AAC.05583-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Poirel L, Revathi G, Bernabeu S, Nordmann P. 2011. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother. 55:934–936. 10.1128/AAC.01247-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA, Garzón Aguilar MI, Martinez de la Barrera L, Barrero Barreto ER, Marquez-Ortiz RA, Moncada Guayazán MV, Vanegas Gómez N. 2013. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob. Agents Chemother. 57:1957–1960. 10.1128/AAC.01447-12 [DOI] [PMC free article] [PubMed] [Google Scholar]